SCHEMBL8440523

SCHEMBL8440523

O=C(CN1CCN(c2cccc([N+](=O)[O-])c2)CC1)OC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
LMNA P02545 2/20 0.56
ALDH1A1 P00352 1/20 0.56
HPGD P15428 1/20 0.56
POLB P06746 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
DRD2 P14416 1/20 0.48
DRD4 P21917 1/20 0.48
DRD3 P35462 1/20 0.48
HTR1A P08908 1/20 0.48
ENPP2 Q13822 5/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
HTR7 P34969 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661913 0.83 POLB (0.50) MAPTLMNAALDH1A1HPGDPOLB
SCHEMBL2658565 0.82 POLB (0.56) MAPTLMNAALDH1A1HPGDPOLB
SCHEMBL2658558 0.82 POLB (0.56) MAPTLMNAALDH1A1HPGDPOLB
SCHEMBL2662051 0.81 MGLL (0.58) MAPTLMNAALDH1A1POLBSMN1; SMN2
SCHEMBL2661929 0.80 SMN1; SMN2 (0.57) LMNAPOLBSMN1; SMN2DRD2DRD3
SCHEMBL5783473 0.80 ENPP2 (0.51) MAPTLMNAALDH1A1POLBSMN1; SMN2
SCHEMBL2658444 0.79 POLB (0.52) MAPTLMNAALDH1A1HPGDPOLB
SCHEMBL2627249 0.77 MAPT (0.69) MAPTLMNAALDH1A1HPGDL3MBTL1
SCHEMBL1842455 0.77 LMNA (0.76) MAPTLMNAALDH1A1HPGDKDM4E
SCHEMBL2659435 0.75 L3MBTL1 (0.61) MAPTLMNAALDH1A1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds NEUROSEARCH A/S 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097570-A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds GABRA1, GABRA2, GABRA4 MAPT 906/4885LMNA 3526/4885ALDH1A1 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.